Anti-IL17A (Cosentyx) (secukinumab biosimilar) mAb
Secukinumab (Cosentyx) is a biologic medication used to treat psoriatic arthritis, moderate to severe plaque psoriasis. Biologics are medicines that are human-made through genetic engineering techniques and closely related to a protein that occurs naturally in the body. Secukinumab blocks an inflammatory protein called IL-17, thus improving joint pain and swelling from arthritis and rash from psoriasis. Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Product Specifications
Product Name Alternative
CTLA-8, CTLA8, IL-17, IL-17A, IL17
Reactivity
Human
Target Antigen
IL17A
Clonality
Monoclonal
Applications
FACS
Purification
Purified from cell culture supernatant by affinity chromatography
Storage Conditions
Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing) .Lyophilized proteins are shipped at ambient temperature.
Applications Notes
FACS 1:100
Isotype
IgG1
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC740679-100 1x 100 µL
CD171 / L1CAM (L1 Cell Adhesion Molecule) (UJ127), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740225-100 1x 100 µL
Major Vault Protein (MVP) (1032), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400204-100 1x 100 µL
Complement C4d (C4D204), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
